Our 2021 materiality assessment
Every four years we conduct a detailed materiality assessment to identify issues that matter most to our stakeholders, and where we have the most potential to create value aligned with our purpose. The assessment informs our strategy and our reporting on ESG topics, and guides our impact performance measurement.
Our latest materiality assessment, conducted in 2021, was based on a survey of more than 500 external stakeholders and 12 000 internal stakeholders, and 140 follow-up interviews.
External stakeholders were drawn from our main stakeholder groups, including patients, customers, partners and shareholders. Internal stakeholders – including senior management – were drawn from across our business divisions. Participants were asked to rank the impact of Novartis across eight impact clusters. Results can be seen in the chart below.
Overall, results were in line with our previous materiality assessment conducted in 2017 and were consistent across stakeholder groups: patient safety, access to healthcare, innovation and ethical business practices were again ranked highly. Although environmental sustainability was ranked lower than other impact clusters, it remains an essential component of our strategy and operating model.
For full details of our 2021 materiality assessment, please see: